当前位置: 首页 > 期刊 > 《中国医学创新》 > 2011年第2期
编号:13191705
对比剂肾病的防治进展(2)
http://www.100md.com 2011年1月15日 《中国医学创新》 2011年第2期
     [3] Solomon RJ, Mehran R, Natarajan MK, et al. Contrast-induced nephropathy and long-term adverse events:cause and effect. Clin J Am Soc Nephrol,2009,4(7):1162-1169.

    [4] 邹古明,颜红兵.造影剂肾病的诊断与治疗现状.中国介入心脏病学杂志,2005,13(3):194-196.

    [5] Stacul F, Adam A, Becker CR, et al. Strategies to reduce the risk of contrast-induced nephropathy. Am J Cardiol,2006,98(6A):59-77.

    [6] 周玉杰.造影剂肾病的中国专家共识(草案).http// www. 365heart.com/comment/html/19077.html.

    [7] Rihal CS, Grill DE. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation, 2002,105(19):2259-2264.

    [8] Nakamura T, Sugaya T, Node K, et al. Urinary excretion of liver-type fatty acidbinding protein in contrast medium-induced nephropathy. Am J Kidney Dis, 2006, 47(3):439-444.

    [9] Heierich MC,Haberle L, Muller V, et al. Nephrotoxicity of iso-osmolar iodixanol compared with nonionic low-osmolar contrast media: meta-analysis of randomized controlled trials. Radiology, 2009, 250(1):68-86.

    [10] Frank H, Werner D, Lorusso V, et al. Simultaneous hemodialysis during coronary angiography fails to prevent radiocontrast-induced nephropathy in chronic renal failure. Clin Nephrol,2003,60(3):176-182.

    [11] 马依彤.造影剂肾病预防的新近展——心房钠尿肽的作用.心脏病学实践,2009(6):431.

    (收稿日期:2010-07-27)

    (本文编辑:郎威), 百拇医药(唐芳芳)
上一页1 2